News
ATTO
22.79
+1.15%
0.26
Weekly Report: what happened at ATTO last week (0831-0904)?
Weekly Report · 09/07 10:32
Primary Markets Group August IPO Update
Seeking Alpha · 09/05 06:30
5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More
NASDAQ · 09/04 18:36
Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday
Benzinga · 09/04 15:26
Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
TipRanks · 09/04 10:30
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC
NASDAQ · 09/04 09:15
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27
NASDAQ · 09/03 16:47
Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway
TipRanks · 09/03 15:55
Morgan Stanley Gives a Buy Rating to Attovia Therapeutics, Inc. (ATTO)
TipRanks · 09/03 13:05
Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO)
TipRanks · 09/03 11:50
Attovia reports Q2 EPS ($4.88), consensus ($4.61)
TipRanks · 09/02 20:15
Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K
Benzinga · 09/02 20:09
*Attovia Therapeutics: Upsized IPO Proceeds of $332.4 M Helps Extend Cash Runway Into 2030 >ATTO
Dow Jones · 09/02 20:07
*Attovia Therapeutics 2Q Rev $450,000 >ATTO
Dow Jones · 09/02 20:07
*Attovia Therapeutics 2Q Loss $20.7M >ATTO
Dow Jones · 09/02 20:05
Press Release: Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Dow Jones · 09/02 20:05
Press Release: Attovia Therapeutics Reports -2-
Dow Jones · 09/02 20:05
Attovia Therapeutics Initiated at Buy by Citigroup
Dow Jones · 08/31 15:15
Attovia Therapeutics Price Target Announced at $30.00/Share by Citigroup
Dow Jones · 08/31 15:15
Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga · 08/31 15:06
More
Webull provides a variety of real-time ATTO stock news. You can receive the latest news about Attovia Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATTO
Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases with high unmet need. Its lead pipeline candidates target commercially validated pathways and are designed through its ATTOBODY biologics platform to deliver improved treatments relative to the standards of care. Its ATTOBODY platform uses an evolution-driven, high-throughput process which allows for discovery and creation of a high diversity of potential product candidates. It is developing a pipeline of novel biotherapeutics for the treatment of immune-mediated diseases. Its first two product candidates for its immune-dermatology franchise, ATTO-1310 and ATTO-2306, have the potential to treat patients suffering from pruritic and lesional diseases. Its third program, ATTO-1091, broadens its reach to other inflammatory diseases, such as IBD, a therapeutic area with substantial unmet need. ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31.